Currently, Enanta Pharmaceuticals Inc [ENTA] is trading at $11.3, up 1.99%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ENTA shares have gain 6.50% over the last week, with a monthly amount glided 25.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enanta Pharmaceuticals Inc [NASDAQ: ENTA] stock has seen the most recent analyst activity on October 01, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $20 for it. On August 09, 2023, downgrade downgraded it’s rating to Underweight but maintained its price target of $14 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $18 on August 08, 2023. H.C. Wainwright initiated its recommendation with a Buy and recommended $56 as its price target on December 09, 2022. Evercore ISI upgraded its rating to Outperform for this stock on July 06, 2022, but kept the price target unchanged to $62. In a note dated June 01, 2022, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $39.
This stock has fluctuated between a low of $4.09 and a high of $15.34 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Enanta Pharmaceuticals Inc [NASDAQ: ENTA] shares were valued at $11.3 at the most recent close of the market. An investor can expect a potential return of 94.69% based on the average ENTA price forecast.
Analyzing the ENTA fundamentals
Trailing Twelve Months sales for Enanta Pharmaceuticals Inc [NASDAQ:ENTA] were 64.81M which represents 1.91% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.49%, Pretax Profit Margin comes in at -1.45%, and Net Profit Margin reading is -1.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.89 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.99 points at the first support level, and at 10.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.58, and for the 2nd resistance point, it is at 11.85.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Enanta Pharmaceuticals Inc [NASDAQ:ENTA] is 5.00. Also, the Quick Ratio is 5.00, while the Cash Ratio stands at 1.01. Considering the valuation of this stock, the price to sales ratio is 5.03, the price to book ratio is 3.05.
Transactions by insiders
Recent insider trading involved Luly Jay R., President and CEO, that happened on Feb 12 ’25 when 45000.0 shares were purchased. Chief Product Strategy Officer, Kieffer Tara Lynn completed a deal on Dec 06 ’24 to sell 2283.0 shares. Meanwhile, Chief Business Officer Luu Brendan sold 2283.0 shares on Dec 06 ’24.
